focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.125
Bid: 17.75
Ask: 18.50
Change: 0.125 (0.69%)
Spread: 0.75 (4.225%)
Open: 18.00
High: 18.125
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of pilot launch and creation of JV

26 Jul 2016 07:00

RNS Number : 1759F
OptiBiotix Health PLC
26 July 2016
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Slimbiome®: Successful completion of pilot launch in GoFigure® shakes and bars Creation of majority owned joint venture agreement with The Healthy Weight Loss Co.  

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the successful completion of a trial launch for its Slimbiome® ingredients in a range of meal replacement shakes and natural snack bars, and its investment to create a majority owned joint venture with The Healthy Weight Loss Company.

 

Slimbiome® is OptiBiotix's patented combination of natural ingredients, identified and developed by experts in nutrition and metabolism, which support scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake of >20% along with reduced levels of cravings. Working in partnership with The Healthy Weight Loss Company, OptiBiotix carried out a test launch of Slimbiome® in GoFigure® snacks and shakes under a non-exclusive UK license agreement. More information can we found at www.GoFigureDiet.com.

 

Following the success of the test launch, OptiBiotix has completed an investment to acquire 51% of The Healthy Weight Loss Company, and see this as a platform to incubate new technological solutions and develop wider product applications in weight management.

• GoFigure® was a finalist in "Best New Health & Nutrition" at the 2016 European Natural & Organic Awards and launched on line in June

• Retail listings have been confirmed with first listings on the shelves from August, and wider discussions taking place 

• Early web based sales are out-performing expectations, and the products are receiving positive reviews and most importantly, dieters are finding the real benefits of this diet plan

 

This incubator model provides an effective way to test early concepts in a large and growing market. The functional foods market is worth £203bn and has potential applications across OptiBiotix's other areas of market focus, including cholesterol and diabetes. Following four weeks of sales, the trial has established that the product, the concept, the supply chain and the delivery and customer service meet consumers' expectations. The reviews from consumers show strong support for the tastes and flavours, and for the efficacy of the product in managing hunger and reducing calorie intake.

 

The progress with this trial and the associated joint venture investment expands the range of commercial opportunities for Slimbiome®. OptiBioitix continues to progress discussions for dietary supplements and over the counter (OTC) applications, both in the UK and internationally. The launch of SlimBiome® in the GoFigure® range establishes the first application in food products and will support discussions with international partners.

 

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are really pleased at the results from the trial and early consumer feedback which provides market evidence for the efficacy of Slimbiome® in reducing calorie intake and managing weight loss which will help leverage discussions with international partners on use of Slimbiome® as a supplement and food and dairy ingredient. We are delighted to partner with the management of The Healthy Weight Loss Company who have extensive experience in the weight management sector. This partnership creates a platform to take our technology developments to market on an accelerated basis providing early consumer feedback which will use to develop future product opportunities both nationally and on a global basis."

 

 

 

 

 

For further information, please contact:

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP

Tel: 020 7148 7900

Liam Murray

Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

Tel: 020 3713 4581

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

 

 

 

About OptiBiotix Health plc - www.optibiotix.com

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCAKPDDABKDBOB
Date   Source Headline
2nd Aug 20167:00 amRNSAppointment of Director of Business Development
28th Jul 20162:30 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSCompletion of pilot launch and creation of JV
14th Jul 20167:00 amRNSNew patent filing
5th Jul 20167:00 amRNSStrategy update
4th Jul 20163:36 pmRNSHolding(s) in Company
30th Jun 20163:06 pmRNSExercise of Warrants and Issue of Equity
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
2nd Jun 201612:18 pmRNSExercise of Warrants and Issue of Equity
19th May 20167:00 amRNSNew patent filing
10th May 201612:39 pmRNSResult of AGM
20th Apr 201612:18 pmRNSExercise of Warrants and Issue of Equity
14th Apr 20167:00 amRNSFinal Results
7th Apr 20167:00 amRNSResults of cholesterol human volunteer study
5th Apr 20167:00 amRNSJoint development agreement signed with Royal DSM
24th Mar 20167:00 amRNSExercise of Warrants and Issue of Equity
23rd Mar 20167:00 amRNSNotice of Results
22nd Mar 20167:00 amRNSSecond contract signed for Sweetbiotix
17th Mar 20167:00 amRNSJV agreement with the University of Manchester
26th Feb 201610:57 amRNSExercise of Warrants and Issue of Equity
19th Feb 201610:12 amRNSExercise of Warrants and Issue of Equity
12th Feb 20169:49 amRNSExercise of Warrants and Issue of Equity
5th Feb 20167:00 amRNSPlacing
28th Jan 201612:51 pmRNSInvestor presentation - change of venue
26th Jan 20167:00 amRNSExercise of Warrants and Issue of Equity
20th Jan 20167:00 amRNSInvestor presentation
19th Jan 20167:00 amRNSScientific Advisory Group appointment
13th Jan 20167:00 amRNSCommercial agreement signed with KSF Acquisition
21st Dec 20157:00 amRNSCompletion of Placing, Total Voting Rights
11th Dec 20151:30 pmRNSCorrection: Exercise of Warrants & Issue of Equity
11th Dec 201511:30 amRNSExercise of Warrants and Issue of Equity
7th Dec 20157:00 amRNSPlacing and Directors' Dealings
24th Nov 20157:00 amRNSDirectorate Change
20th Nov 20157:00 amRNSDevelopment agreement signed with CSL
16th Nov 201510:49 amRNSExercise of Warrants and Issue of Equity
5th Nov 20154:40 pmRNSSecond Price Monitoring Extn
5th Nov 20154:35 pmRNSPrice Monitoring Extension
3rd Nov 20157:00 amRNSNew patent filings
7th Oct 201512:30 pmRNSHolding(s) in Company
7th Oct 20157:00 amRNSNew microbial strain registrations
29th Sep 20157:00 amRNSCompletion of human studies
18th Sep 20154:18 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20157:00 amRNSHalf Yearly Report
11th Aug 201512:08 pmRNSResult of AGM
28th Jul 20157:00 amRNSCompletion of human studies
9th Jul 20157:00 amRNSContract signed with Instituto de Química Orgánica
23rd Jun 20155:00 pmRNSHolding(s) in Company
17th Jun 20154:59 pmRNSExercise of Warrants and Issue of Equity
12th Jun 20152:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.